The HemoScreen instrument is a point-of-care five-part differential complete blood count analyzer that is used for rapid testing from a drop of blood.

The company's CircleDNA and ACT Genomics businesses are on track to achieve business-unit breakeven in the second half of 2024, it said.

The company, based outside of Grenoble in the French Alps, together with its partners has received €5 million to pursue the project.

The company said that gains in its Agilent CrossLab Group offset losses across its other two divisions as the company undertakes restructuring to grow as the market improves.

Called the Coalition for Effective Diagnostics, the organization has called on lawmakers to pass legislation revamping diagnostics regulation, including oversight of LDTs.

The company said that it is pairing its diagnostics and life sciences businesses to support growth and focus on shared end markets and customers.

According to the DOJ, Osman Syed submitted more than $79 million in fraudulent claims to Medicare and Texas Medicaid for RPP testing.

Last week, readers were most interested in a story about the development of an AI-based method to predict COPD flare-ups before symptoms appear.

The story has been corrected to say that the firm is seeking regulatory clearance for its PanCystPro test, not FDA clearance as previously stated. NEW YORK – Startup company Amplified Sciences on ...

VANCOUVER, British Columbia — At the Association for Molecular Pathology annual meeting here this week, leadership briefed members on what to expect as the association's lawsuit challenging the US ...

Scientists in California and Michigan said that their FastGlioma algorithm can improve detection of tumor infiltration at the margins of surgery sites.